Newsroom | 8468 results

DUBLIN--(BUSINESS WIRE)--The "World Market for AI in Medical Imaging 2025-2032" report has been added to ResearchAndMarkets.com's offering. Radiology faces a triple squeeze: rising scan volumes, stagnant radiologist head-count, and fast-evolving reimbursement that now rewards computer-assisted detection, triage, and quantification. AI is no longer experimental; it is operational. Capital allocation is shifting, yet market signals remain noisy - valuations, attach-rate assumptions, and regulator...

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bayer Canada est fière d’annoncer un nouveau partenariat avec Mint Pharmaceuticals Inc. pour la distribution des comprimés ADALAT® XL® à 30 mg1 au Canada. Cette collaboration stratégique est entrée en vigueur le 3 septembre 2025. « Nous sommes ravis de nous associer à Mint Pharmaceuticals Inc., une entreprise réputée pour son engagement en matière de qualité et de service à la clientèle, a déclaré Viktoria Friedrich, présidente nationale et directrice géné...

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bayer Canada is pleased to announce a new partnership with Mint Pharmaceuticals Inc. for the distribution of ADALAT® XL® 30 mg tablets1 in Canada. This strategic collaboration took effect on September 3, 2025. “We are excited to partner with Mint Pharmaceuticals Inc., a company known for its commitment to quality and customer service,” said Viktoria Friedrich, Country President and General Manager at Bayer Inc., Pharmaceutical Division. “This partnership w...

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, a heart health company modernizing cardiovascular drug development, today introduced the three late-stage clinical programs leading its robust pipeline, each strategically chosen to advance the Company’s mission of delivering multiple important medicines at a pace not previously seen in cardiology. These programs target the underlying drivers of specific types of dilated cardiomyopathy (DCM), acute severe hypertension (AS...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that data from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the Heart Failure Society of America (HFSA)’s Annual Scientific Meeting in Minneapolis, Minnesota, September 26-29, 2025. In July 2025, the U.S. Food and Drug Administration (FDA) approved a new indication for KERENDIA to treat adult patients with heart failure (HF) with left ventricular ejection fraction (LVEF) ≥40%, following the age...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced it has entered into an option agreement to acquire Respira Therapeutics (Respira) and its lead product candidate, RT234, an investigational inhaled vardenafil dry‑powder...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI’s TeraRecon, a leading provider of AI-empowered AV clinical workflows, visualization and interoperability solutions, today announced it has surpassed 2,000 global customers. This milestone reflects the continued acceleration of the company’s cloud-first SaaS transformation with an enterprise-level solution used across clinical imaging domains such as vascular surgery, interventional radiology and cardiology, as well as its success of targeted interna...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu®......

HENDERSON, Nev.--(BUSINESS WIRE)--Corstasis Therapeutics Inc., an innovative biopharmaceutical company providing enhanced outpatient therapeutic options for patients with cardiovascular and renal disease, today announced a strategic collaboration with U.S. Heart and Vascular® (USHV), the nation’s premier cardiovascular management services organization, seeking to enable earlier intervention and enhance outcomes for heart failure patients. Corstasis and USHV will co-develop, and seek to optimize...

DENVER--(BUSINESS WIRE)--Cleerly, a leader in AI-based cardiovascular imaging, today announced that Cigna will begin covering Cleerly LABS Advanced Plaque Analysis effective October 1, 2025. The coverage decision makes Cigna the latest major insurer to recognize the clinical and economic value of Artificial Intelligence Enabled CT Based Quantitative Coronary Tomography (AI-QCT)/Coronary Plaque Analysis (AI-CPA) technology for cardiovascular care. With more than 16 million covered lives, Cigna j...